Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0360319950270020284
Journal of Korean Cancer Research Association
1995 Volume.27 No. 2 p.284 ~ p.291
5-Fluorouracil, Ifosfamide, and Cisplatin(FIP) Combination Chemotherapy for Advanced Non-Small Cell Lung Cancer
¼­¿µÀÏ
¹Ú¿µ¼®/ÀÌÀç¸í/ÃÖÁ¶¿µ/±èÇö¼ö/Á¶º´µ¿/¼­À¯¹Ì/ÇÑÀ±Ã¢/±èÈ£Áß
Abstract
We conducted a phase ¥±trial of combining 5-fluorouracil(5-FU), ifosfamide(IFM), and cisplatin(DDP) in previously untreated patients with advanced, unresectable, non-small cell lung cancer(NSCLC). Each cycle consisted of 5-FU 100mg/m* i. v. day
1.
Cycles were repeated at 3 week intervals.
Twenty eight patients were enrolled. Age ranged from 36 to 73(median 57 years); 24 were male, 4 female. Eleven patients had stage ¥²b disease and 17 stage ¥³. Two patients were not evaluable because of lost to follow up. None had a complete
response, 13
patients(50%)had partial responses, 8(31%) had stable diseases, and 5(19%) had progressive diseases. The median response duration was 11.2 weeks; the median time to progression was 12 weeks. The overall median survival was 19 weeks(27.5 weeks for
responders, 12.8 weeks for non-responders). Major side effects were alopecia, nausea/vomiting and stomatitis, all of which were well tolerated and reversible. By univariate analysis, stage and performance status correlated with time to
progression
and
overall survival time.
In conclusion, FIP combination chemotherapy for patients with advanced, unresectable non-small cell lung cancer seems to be an effective and well-tolerated regimen.
KEYWORD
FullTexts / Linksout information
 
Listed journal information
KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø